What does the FDA label expansion for Ionis Tryngolza mean for severe hypertriglyceridemia?

The FDA has expanded Tryngolza’s label, making it the first approved treatment specifically for severe hypertriglyceridemia. The move broadens Ionis’ commercial reach and signals growing regulatory confidence in antisense therapies for chronic metabolic conditions, potentially strengthening the company’s RNA‑based franchise.